pozelimab

Home
Ligands
pozelimab

GtoPdb Ligand ID: 12900

Synonyms: pozelimab-bbfg | REGN-3918 | REGN3918 | Veopoz®

pozelimab is an approved drug (FDA (2023))

Comment: Pozelimab (REGN-3918) targets the terminal complement component C5 [1]. It is designed to inhibit complement pathway activation and complement-mediated inflammatory tissue damage.

Summary
Biological activity
Clinical data
References
Immunopharmacology

References
1. Latuszek A, Liu Y, Olsen O, Foster R, Cao M, Lovric I, Yuan M, Liu N, Chen H, Zhang Q et al.. (2020) Inhibition of complement pathway activation with Pozelimab, a fully human antibody to complement component C5. PLoS One, 15 (5): e0231892. [PMID:32384086]

References

1. Latuszek A, Liu Y, Olsen O, Foster R, Cao M, Lovric I, Yuan M, Liu N, Chen H, Zhang Q et al.. (2020)
Inhibition of complement pathway activation with Pozelimab, a fully human antibody to complement component C5.
PLoS One, 15 (5): e0231892. [PMID:32384086]